 
                Chemical Structure : SB-525334
CAS No.: 356559-20-1
Catalog No.: PC-42858Not For Human Use, Lab Use Only.
SB-525334 is a potent and selective inhibitor of TGF-β1 receptor (ALK5) inhibitor with IC50 of 14,5 nM, 4-fold less potent against ALK4 and inactive for ALK2, ALK3, and ALK6 (IC50>10 uM).
| Packing | Price | Stock | Quantity | 
|---|---|---|---|
| 10 mg | $78 | In stock | |
| 25 mg | $138 | In stock | |
| 50 mg | $218 | In stock | |
| 100 mg | Get quote | 
Bulk size, bulk discount!
Welcome credit card payment!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
	SB-525334 is a potent and selective inhibitor of TGF-β1 receptor (ALK5) inhibitor with IC50 of 14,5 nM, 4-fold less potent against ALK4 and inactive for ALK2, ALK3, and ALK6 (IC50>10 uM).
	SB 525334 blocks TGFβ1-induced phosphorylation and nuclear translocation of Smad2/3 in renal proximal tubule cells and inhibits TGFβ1-induced increases in PAI-1 and procollagen α1 mRNA expression in A498 renal epithelial carcinoma cells at 1 uM.
	SB 525334 significantly inhibits PAN-induced proteinuria in rat model of nephritis-induced renal fibrosis.
| M.Wt | 343.4249 | |
| Formula | C21H21N5 | |
| Appearance | Solid | |
| Storage | 
 | 
 | 
| Solubility | DMSO: ≥ 46 mg/mL | |
| Chemical Name/SMILES | Quinoxaline, 6-[2-(1,1-dimethylethyl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-4-yl]- | |
1. Grygielko ET, et al. J Pharmacol Exp Ther. 2005 Jun;313(3):943-51.
2. Laping NJ, et al. Clin Cancer Res. 2007 May 15;13(10):3087-99.
3. Thomas M, et al. Am J Pathol. 2009 Feb;174(2):380-9.
4. Kim YJ, et al. Anticancer Res. 2012 Mar;32(3):799-806.

 
                 
                 
                 
                 
                 
                 
                 
                 
            
            
        Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright